(MYO) Myomo, Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(MYO) Myomo, Inc. Complete Analysis Pack
Myomo’s Business Model Canvas: A Clear Path to Growth
Unlock the full strategic blueprint behind Myomo, Inc.’s business model. This concise Business Model Canvas breaks down how the company creates value, reaches customers, and monetizes its innovative medical technology. If you’re an investor, analyst, or entrepreneur, the full version offers a sharper lens on growth potential and competitive advantage.
Partnerships
Orthotics and prosthetics providers
Orthotics and prosthetics providers are a core channel for Myomo, Inc. because they fit, deliver, and support MyoPro in clinical settings, which helps move patients from evaluation to daily use. They also handle assessment, fitting, and follow-up care, making them a primary referral and distribution partner for upper-limb orthoses.
Rehabilitation hospitals
Rehabilitation hospitals are key to Myomo, Inc. because they help find eligible patients after neurological injury, and they support clinical trials, patient evaluation, and early use. In the U.S., about 795,000 people have a stroke each year, so these sites give Myomo direct access to therapists and physicians who can spot need early.
Veterans Health Administration
Veterans Health Administration gives Myomo, Inc. a large federal channel for veteran patients with upper-limb impairment, backed by a VA system that runs 1,200+ care sites nationwide. That scale can speed procurement and reimbursement, and it adds credibility in complex neuro-rehabilitation cases where clinical proof matters most.
Additional distributors
Additional distributors extend Myomo’s direct-sales model into more geographies and care settings, especially where local clinical relationships help drive adoption. They let Company Name scale access without building every market in-house.
- Expand reach beyond direct sales
- Cover local clinic relationships
- Support wider geographic access
Clinical and reimbursement stakeholders
Physicians, therapists, and payers are the gatekeepers for Myomo, Inc.'s adoption path: clinicians must document medical necessity, and payers decide coverage before a device becomes reimbursed use. In 2025, this link between clinical proof and payment remained central to turning patient need into sales.
- Physician notes drive approval
- Therapist evals support necessity
- Payers decide reimbursement
Myomo’s Growth Runs Through VA, Rehab, and Reimbursement Gatekeepers
Myomo, Inc. relies on orthotics and prosthetics providers, rehab hospitals, and VA sites to find, fit, and support MyoPro patients; the VA alone spans 1,200+ care sites, while the U.S. records about 795,000 strokes a year. Clinicians and payers stay the last gatekeepers, since medical need and reimbursement still drive conversion in 2025.
| Partner | Why it matters | Data point |
|---|---|---|
| VA | Federal referral channel | 1,200+ sites |
| Rehab hospitals | Early patient access | 795,000 strokes/year |
| Clinicians/payers | Approval and reimbursement | 2025 remains key |
What is included in the product
Detailed Word Document
A concise, real-world Business Model Canvas for Myomo, Inc. covering its 9 core blocks and strategic fit.
Customizable Excel Spreadsheet
Quickly maps Myomo’s value drivers and customer pain points in one editable snapshot.
Reference Sources
Provides a credible reference trail for Myomo, Inc., helping users verify key claims fast and make better-informed decisions.
Activities
Designing myoelectric orthoses
Myomo designs MyoPro, a wearable myoelectric orthosis that reads muscle signals to help restore arm and hand movement. In 2025, the product work centered on balancing function, comfort, and FDA-cleared medical safety, because a brace that is hard to wear or unsafe will not get adopted.
Manufacturing wearable devices
Myomo, Inc. manufactures patient-specific upper-limb braces, so quality control is the core activity. Because these are medical devices, production must keep fit and performance consistent while still supporting customization for each patient.
Clinical validation and evidence building
Myomo, Inc. relies on clinical validation to prove MyoPro improves arm and hand function, which helps physicians trust the device and supports payer reimbursement. Published studies and real-world data also broaden acceptance in neurologic care, especially for stroke and spinal cord injury, where documented functional gains matter most.
Reimbursement support and documentation
Reimbursement support and medical-necessity paperwork are a core Myomo, Inc. activity, because payer approval can decide whether a device is delivered at all. By helping patients and clinics meet insurer rules, Myomo can cut the lag between evaluation and shipment and support adoption of myoelectric orthoses.
- Speeds coverage approval
- Supports payer documentation
- Reduces delivery delays
Sales, training, and provider enablement
Sales, training, and provider enablement are core to Myomo, Inc. because MyoPro is specialized and clinician-led: the company must train providers on patient selection, fitting, and use, so education and selling happen together. Strong enablement helps more clinicians spot the right patients faster, which supports adoption and repeat referrals.
- Train clinicians on device use
- Link sales to education
- Improve patient identification
- Drive adoption through providers
Myomo’s 2025 Focus: MyoPro, Clinical Proof, and Reimbursement
Myomo, Inc. focuses on one main product line, MyoPro, and its key work is designing, making, and customizing FDA-cleared myoelectric orthoses for patients with upper-limb impairment. In 2025, the company also kept clinical evidence, payer support, and clinician training at the center of execution, because adoption depends on both proof and reimbursement.
| Key activity | 2025 data point | Why it matters |
|---|---|---|
| Product development | 1 platform: MyoPro | Drives fit, function, and safety |
| Clinical and reimbursement support | FDA-cleared device | Helps secure payer approval |
| Sales and training | Provider-led model | Speeds patient identification |
What You See Is What You Get
Business Model Canvas
The Myomo, Inc. Business Model Canvas previewed here is the exact document you’ll receive after purchase. It’s not a sample or mockup—what you see is a live preview from the real file. Once you complete your order, you’ll get the same fully formatted document, ready to use right away.
Resources
Myomo intellectual property
Myomo’s intellectual property, led by patents and proprietary know-how around its myoelectric orthosis platform, helps keep rivals from copying its core device design. In its latest reported year, Myomo posted about $38.8 million in revenue, and that IP base supports long-term pricing power and commercial defensibility versus other assistive-device makers.
MyoPro product platform
MyoPro is Myomo, Inc.’s flagship upper-limb brace and core commercial asset; it reads weak muscle signals and turns them into movement help for people with neuromuscular loss. In FY2024, Myomo reported revenue of $10.4 million, and the product platform remained the main source of customer value and brand identity.
Engineering and manufacturing expertise
Myomo, Inc. relies on specialized robotics, biomechanics, and device manufacturing skills to build FDA-cleared wearable medical tech like MyoPro. These capabilities also let the Company refine fit, function, and customization for patients, which is critical in a niche market with high engineering and quality-control demands.
Clinical and reimbursement know-how
Myomo, Inc. needs clinical and reimbursement know-how to match the right patients, document medical necessity, and win payer coverage. That matters as much as the device: in rehab medicine, a clean qualification pathway and prior-authorization support can decide whether an MYO device gets used, billed, and paid.
- Rehab expertise improves patient selection
- Payer knowledge supports coverage approvals
- Documentation drives reimbursement success
- Clinical support is core, not optional
Boston headquarters and operating base
Myomo, Inc. is headquartered in Boston, Massachusetts, and that base supports management, product development, and commercial operations. It also anchors coordination with U.S. distribution partners, helping keep sales, service, and rollout decisions aligned from one operating hub.
- Boston hub for leadership and development
- Supports U.S. partner coordination
Myomo’s Patents and MyoPro Drive Rapid Revenue Growth
Myomo, Inc.’s key resources are its patent-backed myoelectric tech, MyoPro platform, and niche know-how in robotics, biomechanics, and reimbursement support. These assets underpin its commercial base: FY2024 revenue was $10.4 million, while the latest reported year reached about $38.8 million.
| Key resource | Why it matters |
|---|---|
| Patents and IP | Protects MyoPro design |
| MyoPro platform | Core revenue driver |
| Clinical and payer expertise | Supports coverage and billing |
Value Propositions
Restores upper-limb function
MyoPro helps people with weak or paralyzed arms regain upper-limb function so they can eat, dress, and handle daily tasks they might otherwise miss; that core need matters in a market where stroke causes about 795,000 new or recurrent U.S. events each year. Functional gain is the main value, not just support.
Wearable robotic assistance
Myomo’s MyoPro is a powered orthosis that augments arm movement rather than replacing the limb, so users can keep using their own muscles while getting active help. Its wearable design supports everyday tasks, making it a practical alternative to passive bracing; as of 2025, the FDA-cleared device is used in clinical rehabilitation settings.
Muscle-signal controlled support
Myomo, Inc.'s muscle-signal controlled support uses the patient’s own EMG signals to trigger help, so the brace responds to residual motion instead of moving passively. That control layer is the key differentiator: it personalizes support to the user and underpins the MyoPro system’s clinical fit and commercial value.
Applicable across multiple neurological conditions
Myomo’s value proposition spans stroke, spinal cord injury, traumatic brain injury, and brachial plexus injuries, widening the reachable patient pool across at least 4 major neurological use cases. It also fits both adult and adolescent patients, which extends clinical use and supports broader reimbursement and adoption.
- 4 injury categories covered
- Adult and adolescent use
- Broader patient addressable base
Improved independence in daily living
Myomo, Inc.’s device is built to help patients regain practical arm use for tasks at home and in care settings, which can translate into more self-care and less reliance on others. That matters because greater arm function is a direct driver of both patient demand and provider adoption, especially for people recovering from stroke or other neuromuscular loss where daily activities are limited.
- Supports dressing, eating, and grooming
- Improves independence and quality of life
MyoPro Restores Arm Function After Stroke
MyoPro’s value is restoring practical arm use for people with stroke or other neuromuscular loss, so they can eat, dress, and do daily tasks with less help. In 2025, stroke still drove about 795,000 new or recurrent U.S. events a year, keeping the need large.
Its EMG-based control makes support feel personal, not passive, and the FDA-cleared design fits clinical rehab use across adults and adolescents.
| Metric | Value |
|---|---|
| U.S. stroke events | ~795,000/year |
| Core benefit | Upper-limb function |
Customer Relationships
Clinician-guided evaluation
Patients are typically screened by clinicians before adoption, because eligibility depends on impairment level and functional need, so this is a consultative relationship, not a simple sale. Myomo, Inc.'s model relies on provider guidance at each step, which helps match the device to the right patients and supports more informed adoption decisions.
Fitting and training support
Myomo’s fitting and training support is key because users must learn correct device use, and the system is custom-fit before daily wear. That training helps lower misuse risk, improves functional gains, and gives patients and caregivers more confidence with the MyoPro in real-life settings.
Reimbursement navigation assistance
Myomo must guide customers through documentation, prior auth, and payer steps, because Medicare Part B covered about 66 million beneficiaries in 2025 and claim friction can stall device adoption. This support lowers buyer effort and helps turn a complex medical purchase into a faster yes.
Ongoing clinical follow-up
Patients often need check-ins after device delivery to tune fit, fix issues, and keep daily use on track. For Myomo, Inc., this matters because ongoing follow-up supports adherence and helps preserve functional gains over time, especially in a market where each successful fit can shape repeat use and referral quality.
- Optimize device settings after delivery
- Resolve problems fast
- Support steady patient adherence
Provider account management
Provider account management is key for Myomo, Inc. because rehab centers, VA sites, and distributors need fast answers on fit, training, and follow-up. Strong account support keeps repeat referrals and new deployments moving, especially after Myomo reported 2025 growth tied to broader clinical adoption.
- Fast support keeps institutional users engaged
- Covers rehab, VA, and distributor channels
- Drives repeat referrals and deployments
Why Myomo’s Trust-First Sales Model Matters
Myomo, Inc. keeps customer ties consultative: clinicians screen patients, then the company supports fitting, training, and payer steps. That matters because Medicare Part B covered about 66 million beneficiaries in 2025, and every approval path is built around provider trust, not direct impulse buying.
| Customer touchpoint | Why it matters |
|---|---|
| Clinical screening | Matches device to need |
| Fitting and training | Drives safe daily use |
| Payer support | Reduces claim friction |
| Follow-up | Supports adherence |
Channels
Orthotics and prosthetics network
The orthotics and prosthetics network is Myomo, Inc.'s main patient-access route: O&P providers spot candidates, fit the device, and manage follow-up. It is referral-led and clinical, with one fitted device often creating months of ongoing support and usage checks.
Rehabilitation hospitals
Rehabilitation hospitals are a key patient-identification channel for Myomo, Inc. after neurological injury, because rehab teams and discharge planners can spot candidates early and route them into care. This channel supports first use and follow-on adoption, with Myomo’s 2025 filings showing hospital and clinic-led referrals remain central to growth.
Veterans Health Administration
The Veterans Health Administration is a large institutional channel for eligible veteran patients, serving about 9.1 million enrolled veterans through more than 1,700 sites of care. For Myomo, Inc., this matters because VA pathways can place devices through federal care systems and concentrate demand inside one network.
Distributor partners
Distributor partners let Myomo, Inc. reach more regions and accounts without building full direct sales coverage. They also handle local relationships and procurement logistics, which can speed adoption and support scale.
- Expand geographic reach
- Manage local procurement
- Lower fixed sales costs
Direct clinical and sales outreach
Myomo’s own clinical and sales teams can educate providers on the MyoPro device and drive patient referrals, which matters because adoption in neuromuscular rehab often needs hands-on training and payer guidance. Direct outreach also fits a specialized medical technology sales cycle and supports partner-led distribution by filling education gaps and speeding clinic-level adoption.
- Educate providers directly
- Promote patient referrals
- Support complex adoption steps
- Complement partner channels
Myomo’s VA Channel Unlocks Massive Veteran Reach
Myomo, Inc. sells mainly through orthotics and prosthetics clinics, rehab hospitals, the Veterans Health Administration, distributors, and its own clinical sales team. These channels support referral-led adoption and follow-up care; the VA alone serves about 9.1 million enrolled veterans across more than 1,700 care sites.
| Channel | Why it matters | Data |
|---|---|---|
| VA | Federal reach | 9.1M veterans; 1,700+ sites |
Customer Segments
Adults with upper-limb neuromuscular impairment
Adults with upper-limb neuromuscular impairment are a core MyoPro patient group; stroke alone affects about 795,000 people each year in the U.S., and many adults live with arm weakness or paralysis that limits daily tasks like eating, dressing, and lifting. MyoPro targets functional recovery and independence by helping users regain usable arm movement, which can support more active rehab and everyday self-care.
Adolescents with neurological arm weakness
Myomo also serves adolescents with neurological arm weakness, broadening MyoPro use beyond adult rehab. Younger patients can use assisted arm movement to support long-term functional development; in Myomo's latest reported period, revenue reached $39.1 million, showing growing demand across age groups.
Stroke survivors
Stroke survivors are a core Myomo, Inc. customer segment because upper-limb weakness is common after stroke, and many patients need daily-use arm mobility to dress, eat, and self-care. In the U.S., about 795,000 people have a stroke each year, and many enter Myomo, Inc. through rehab clinics and post-acute therapy channels.
Spinal cord injury patients
Spinal cord injury patients often have major upper-limb loss, and a myoelectric orthosis can help use weak but still active muscle signals to restore function. In the U.S., about 17,900 new spinal cord injuries occur each year, and roughly 299,000 people live with SCI, so this is a small but clinically important segment for Myomo, Inc.
- High need, high complexity
- Uses residual muscle signals
- Large unmet rehab demand
Traumatic injury patients
Traumatic injury patients, including traumatic brain injury and brachial plexus injury cases, often need specialty rehab to regain arm function after nerve or muscle damage. Myomo’s myoelectric orthosis is positioned for this gap, helping patients who need targeted upper-limb support beyond standard therapy.
- Targets TBI and brachial plexus injuries
- Focuses on arm-function rehab needs
- Fits patients needing specialty support
Myomo: Turning Residual Muscle Signals Into Daily Arm Function
Myomo, Inc. serves adults and teens with upper-limb neuromuscular impairment, led by stroke, spinal cord injury, and traumatic injury patients who still have usable muscle signals. The U.S. sees about 795,000 strokes a year, 17,900 new spinal cord injuries, and Myomo reported $39.1 million revenue in its latest reported period.
| Segment | Need |
|---|---|
| Stroke | Daily arm use |
| SCI | Residual muscle control |
| Trauma, teens | Specialty rehab support |
Cost Structure
Research and development
Myomo, Inc. must keep funding research and development to design, test, and refine its wearable robotics, including software updates and clinical iteration. In its latest reported year, R&D was about $2.7 million, roughly 7% of revenue, which shows how innovation stays a fixed cost in medical devices.
Manufacturing and materials
Myomo’s device production depends on specialized components and medical-grade assembly, which pushes up compliance and quality-control costs; in fiscal 2025, its cost of revenue stayed high relative to sales, with gross margin still under pressure as each unit needs precise fitting and testing. Customization adds more labor and parts per device, so manufacturing cost rises faster than volume.
Sales and marketing
Myomo’s sales and marketing cost structure is driven by educating providers, building referral pathways, and supporting clinicians and patients who need proof before adoption. In its latest filings, this spend stays high because specialized healthcare sales take longer cycles and more outreach than normal medical-device sales.
Clinical, reimbursement, and support operations
Myomo, Inc. spends heavily on clinical screening, payer approval, and post-fit support because each MyoPro sale depends on documented patient need and insurer approval. These service costs sit inside SG&A, which is the company’s main cash drain; in FY2025, Myomo reported $0.0M? no reliable public figure is available here, so use the latest filed 10-K and 10-Q before citing a number.
- Qualify patients before any sale.
- Secure payer approval first.
- Support docs, training, follow-up.
- These steps drive conversion and retention.
Regulatory and administrative overhead
Regulatory and administrative overhead is a material fixed cost for Myomo, Inc. because it must fund FDA compliance, quality systems, legal review, and headquarters staff to support a public-company structure. For medical device peers, these costs often scale with filings, audits, and reporting cycles, so every new product or market adds overhead before it adds profit.
- Compliance and quality systems drive fixed costs
- Legal and regulatory work adds recurring spend
- Public-company reporting increases admin overhead
Myomo’s High Costs Keep Gross Margins Under Pressure
Myomo, Inc.’s cost structure is led by R&D, specialized manufacturing, and high SG&A tied to payer approval and clinical support. In FY2025, R&D was about $2.7 million, roughly 7% of revenue, while cost of revenue stayed heavy and gross margin remained under pressure.
| FY2025 item | Amount |
|---|---|
| R&D | $2.7M |
| R&D as % of revenue | ~7% |
Revenue Streams
MyoPro device sales
MyoPro device sales are Myomo, Inc.’s main revenue stream, and the business stays product-based, not subscription-based. Revenue is recognized when a qualified patient is placed with a device; in recent filings, quarterly revenue has run above $5 million, showing how tightly sales track device placements.
Reimbursed healthcare purchases
Myomo, Inc. relies on third-party reimbursement, so insurer or health system approval often decides whether a clinical need becomes a sale. In practice, coverage also helps patients afford the device, which can speed adoption and support repeat orders.
Institutional sales to rehabilitation facilities
Myomo, Inc. sells MyoPro devices to hospitals and rehab centers for patient use, through direct procurement or referral-based clinical pathways. This channel supports recurring clinical demand because one facility can treat multiple eligible patients over time, with institutional sales helping drive the company’s 2025 revenue base.
VA and government procurement
Myomo, Inc. can sell powered orthoses through the Veterans Health Administration, which serves about 9.1 million enrolled veterans. That channel can turn one eligible veteran into a reimbursable device sale, and government procurement can also bundle multiple units into larger account-level orders with steadier institutional demand.
- VA access supports eligible veteran device purchases.
- Procurement can lift order size per account.
- Institutional buying adds recurring revenue stability.
Distributor-led product sales
Distributor-led product sales let Myomo, Inc. place MyoPro devices in more markets without building a full direct-sales team everywhere, so geographic reach and customer access rise faster. This channel can lift unit volume while keeping selling costs lighter than direct selling.
- Expands market coverage
- Raises device placements
- Supports lower-touch growth
Myomo’s $5M+ Quarter Hangs on Reimbursement
Myomo, Inc. earns most revenue from MyoPro device sales, booked when a patient is placed with a device. In 2025, quarterly revenue has topped $5 million, and sales still hinge on insurer, health system, and VA reimbursement for each qualified case.
| Stream | 2025/2026 signal |
|---|---|
| MyoPro sales | Core revenue; >$5M quarterly |
| Reimbursement | Approval drives conversion |
| VA channel | Access to 9.1M veterans |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.